S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
Log in
OTCMKTS:SONVY

Sonova Competitors

$52.13
-1.38 (-2.58 %)
(As of 02/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$51.91
Now: $52.13
$52.38
50-Day Range
$48.30
MA: $51.28
$54.02
52-Week Range
$29.41
Now: $52.13
$54.77
Volume26,915 shs
Average Volume17,872 shs
Market Capitalization$16.78 billion
P/E Ratio34.98
Dividend YieldN/A
Beta0.7

Competitors

Sonova (OTCMKTS:SONVY) Vs. VAR, MASI, GNGBY, LIVN, CNMD, and INMD

Should you be buying SONVY stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Sonova, including Varian Medical Systems (VAR), Masimo (MASI), Getinge (GNGBY), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

Sonova (OTCMKTS:SONVY) and Varian Medical Systems (NYSE:VAR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 87.0% of Varian Medical Systems shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Sonova has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and Varian Medical Systems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
Varian Medical Systems36001.67

Varian Medical Systems has a consensus price target of $148.2778, suggesting a potential downside of 15.65%. Given Varian Medical Systems' higher possible upside, analysts plainly believe Varian Medical Systems is more favorable than Sonova.

Earnings and Valuation

This table compares Sonova and Varian Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion5.68$489.96 million$1.4934.98
Varian Medical Systems$3.17 billion5.10$269.20 million$3.9144.96

Sonova has higher earnings, but lower revenue than Varian Medical Systems. Sonova is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sonova and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
Varian Medical Systems8.50%18.45%8.08%

Summary

Varian Medical Systems beats Sonova on 10 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and Masimo (NASDAQ:MASI) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Sonova and Masimo's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion5.68$489.96 million$1.4934.98
Masimo$937.84 million14.57$196.22 million$3.2277.10

Sonova has higher revenue and earnings than Masimo. Sonova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Sonova and Masimo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
Masimo02502.71

Masimo has a consensus price target of $262.8333, suggesting a potential upside of 5.59%. Given Masimo's stronger consensus rating and higher possible upside, analysts clearly believe Masimo is more favorable than Sonova.

Risk & Volatility

Sonova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are held by institutional investors. Comparatively, 81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sonova and Masimo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
Masimo20.30%15.75%13.12%

Summary

Masimo beats Sonova on 12 of the 14 factors compared between the two stocks.

Getinge (OTCMKTS:GNGBY) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Getinge and Sonova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Getinge11202.25
Sonova06302.33

Profitability

This table compares Getinge and Sonova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Getinge10.51%17.30%7.90%
SonovaN/AN/AN/A

Insider and Institutional Ownership

0.0% of Getinge shares are held by institutional investors. Comparatively, 1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Getinge has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Earnings and Valuation

This table compares Getinge and Sonova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Getinge$2.81 billion2.35$129.29 millionN/AN/A
Sonova$2.96 billion5.68$489.96 million$1.4934.98

Sonova has higher revenue and earnings than Getinge.

Summary

Sonova beats Getinge on 7 of the 11 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Risk & Volatility

Sonova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Sonova and LivaNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
LivaNova03402.57

LivaNova has a consensus price target of $66.7143, suggesting a potential downside of 9.82%. Given LivaNova's stronger consensus rating and higher probable upside, analysts clearly believe LivaNova is more favorable than Sonova.

Profitability

This table compares Sonova and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
LivaNova-21.88%5.55%3.07%

Valuation & Earnings

This table compares Sonova and LivaNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion5.68$489.96 million$1.4934.98
LivaNova$1.08 billion3.34$-155,180,000.00$3.0824.21

Sonova has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Sonova, indicating that it is currently the more affordable of the two stocks.

Summary

LivaNova beats Sonova on 9 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and CONMED (NYSE:CNMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Sonova has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and CONMED, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
CONMED02402.67

CONMED has a consensus price target of $104.60, suggesting a potential downside of 18.20%. Given CONMED's stronger consensus rating and higher probable upside, analysts clearly believe CONMED is more favorable than Sonova.

Profitability

This table compares Sonova and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
CONMED0.04%9.48%3.75%

Earnings & Valuation

This table compares Sonova and CONMED's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion5.68$489.96 million$1.4934.98
CONMED$955.10 million3.83$28.62 million$2.6448.42

Sonova has higher revenue and earnings than CONMED. Sonova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Sonova on 9 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and InMode (NASDAQ:INMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Profitability

This table compares Sonova and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
InMode32.57%28.56%24.14%

Risk and Volatility

Sonova has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and InMode, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
InMode00403.00

InMode has a consensus price target of $71.50, suggesting a potential upside of 0.48%. Given InMode's stronger consensus rating and higher probable upside, analysts clearly believe InMode is more favorable than Sonova.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sonova and InMode's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion5.68$489.96 million$1.4934.98
InMode$156.36 million14.55$61.15 million$1.6044.48

Sonova has higher revenue and earnings than InMode. Sonova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats Sonova on 11 of the 13 factors compared between the two stocks.


Sonova Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.78-0.0%$16.14 billion$3.17 billion59.99Analyst Downgrade
Masimo logo
MASI
Masimo
1.4$248.25-0.0%$13.67 billion$937.84 million64.48Earnings Announcement
News Coverage
GNGBY
Getinge
0.7$25.97-3.1%$6.60 billion$2.81 billion21.46Upcoming Earnings
Gap Up
LivaNova logo
LIVN
LivaNova
1.5$74.58-0.7%$3.60 billion$1.08 billion-17.34Earnings Announcement
Gap Up
CNMD
CONMED
1.6$127.82-2.3%$3.57 billion$955.10 million-3,195.50Insider Selling
INMD
InMode
1.5$71.16-1.2%$2.25 billion$156.36 million51.19
OM
Outset Medical
0.9$50.50-3.4%$2.08 billionN/A0.00
BioLife Solutions logo
BLFS
BioLife Solutions
1.9$39.88-1.0%$1.29 billion$27.37 million-54.63
TMDX
TransMedics Group
1.2$40.40-8.9%$1.00 billion$23.60 million-28.86Upcoming Earnings
Analyst Report
News Coverage
AxoGen logo
AXGN
AxoGen
1.3$21.83-2.0%$869.25 million$106.71 million-34.65Earnings Announcement
Analyst Report
NTUS
Natus Medical
1.1$26.26-4.0%$853.47 million$495.52 million-47.75Upcoming Earnings
News Coverage
SMLR
Semler Scientific
1.2$104.00-3.8%$696.90 million$32.77 million73.24Upcoming Earnings
ViewRay logo
VRAY
ViewRay
1.3$4.64-1.5%$678.65 million$87.78 million-5.21
Cutera logo
CUTR
Cutera
1.3$38.20-2.0%$659.83 million$181.71 million-21.10Analyst Upgrade
Gap Down
ZYXI
Zynex
1.8$18.15-0.4%$627.77 million$45.47 million55.00Upcoming Earnings
STXS
Stereotaxis
1.0$5.56-1.4%$403.80 million$28.90 million-50.55Upcoming Earnings
Edap Tms logo
EDAP
Edap Tms
1.1$9.70-2.0%$275.79 million$50.23 million-161.67Gap Down
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$2.70-1.1%$212.58 millionN/A-3.55Upcoming Earnings
Gap Down
BSGM
BioSig Technologies
1.2$4.72-1.9%$142.23 millionN/A0.00Upcoming Earnings
FONR
FONAR
1.0$19.80-0.3%$129.38 million$85.69 million18.68
ECOR
electroCore
1.2$2.30-8.3%$95.91 million$2.39 million-2.91News Coverage
Gap Down
Electromed logo
ELMD
Electromed
2.0$10.83-2.7%$91.01 million$32.47 million25.79
IRIDEX logo
IRIX
IRIDEX
0.9$6.76-9.2%$85.33 million$43.45 million-12.29
NDRA
ENDRA Life Sciences
0.6$2.20-8.2%$66.51 million$10,000.00-1.20Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
1.3$2.00-4.0%$44.39 million$3.38 million-1.05Gap Down
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
1.0$6.50-12.2%$40.09 million$15.09 million0.00Upcoming Earnings
Gap Up
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
HSDT
Helius Medical Technologies
1.0$14.00-6.1%$32.35 million$1.50 million-0.80Gap Up
PEYE
Precision Optics
0.4$1.69-0.0%$22.37 million$9.92 million-16.90
CHF Solutions logo
CHFS
CHF Solutions
1.7$8.31-2.9%$22.08 million$5.51 million-0.17Upcoming Earnings
Gap Down
Digirad logo
DRAD
Digirad
1.4$3.94-5.3%$18.75 million$114.18 million-1.25Gap Up
STRR
Star Equity
0.1$4.32-8.8%$18.75 million$114.18 million-1.38Gap Down
VASO
Vaso
0.9$0.09-33.3%$16.67 million$75.75 million4.50News Coverage
Gap Up
MICR
Micron Solutions
0.3$3.25-6.8%$10.93 million$17.50 million23.22
GTHP
Guided Therapeutics
0.3$0.80-11.3%$10.54 million$40,000.00-3.33
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.90-3.3%$8.16 million$6.57 million-0.01Gap Down
NIMU
Non-Invasive Monitoring Systems
0.5$0.04-0.0%$3.16 millionN/A0.00
MAGAA
Magna-Lab
0.7$2.47-9.3%$2.91 millionN/A13.72Gap Up
SCIE
SpectraScience
0.5$0.00-0.0%$1.94 millionN/A0.00
RSLSD
ReShape Lifesciences
0.5N/AN/A$1.94 million$610,000.000.00High Trading Volume
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.04-47.6%$467,000.00N/A0.00Gap Up
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.16-6.2%$327,000.00N/A0.00Gap Down
ULGX
Urologix
0.6$0.01-0.0%$241,000.00N/A0.00Gap Up
IMRIS logo
IMRSQ
IMRIS
0.5$0.00-333.3%$156,000.00N/A0.00
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
ESMC
Escalon Medical
0.6$0.18-0.0%$0.00$9.40 million-3.00Upcoming Earnings
High Trading Volume
Gap Up
HRTT
Heart Tronics
0.0$0.02-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-0.0%$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.